Cigna Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

What Analyst Projections for Key Metrics Reveal About Cigna (CI) Q3 Earnings

Earnings report AI-generated analysis

πŸ“ˆ Analysts project Cigna quarterly earnings of $7.46 per share, indicating a year-over-year decline of 4.7%.

πŸ’° Revenue is expected to reach $73.53 billion, representing a 5.7% increase from the prior-year quarter.

πŸ“Š There have been no revisions to the consensus EPS estimate over the last 30 days.

πŸ₯ Evernorth Health Services revenues are forecasted at $64.06 billion, up 6.1% year over year.

πŸ₯ Cigna Healthcare revenues are projected to hit $11.65 billion, a 6.6% increase from the prior quarter.

πŸ’΅ U.S. Commercial stop-loss premiums are estimated at $2.18 billion, showing a strong 14.1% year-over-year rise.

πŸ‘₯ Total medical customers are expected to reach 18.37 million, surpassing last year's 18.06 million.

πŸ’Š Pharmacy claim volume is forecasted to decrease slightly to 553.94 million from the prior year's 558.00 million.

πŸ“‰ International health covered lives are projected at 1.62 million, down from 1.71 million in the same quarter last year.

πŸ“ˆ Cigna shares have gained 10.2% over the past month, outperforming the S&P 500's -0.9% change.

βš–οΈ Zacks Investment Research maintains a Rank #3 (Hold) rating for CI, expecting market-mirroring performance.

Bullish Signals
  • Cigna shares have demonstrated strong recent returns of +10.2% over the past month, significantly outperforming the S&P 500 composite's -0.9% change.
  • Analysts project a robust 5.7% year-over-year revenue increase to $73.53 billion for the upcoming quarter.
  • U.S. Commercial stop-loss premiums are forecasted to surge by 14.1% year over year, reaching an estimated $2.18 billion.
  • Total medical customers are expected to grow to 18.37 million, exceeding the previous year's total of 18.06 million.
  • Cigna Healthcare revenues are projected to rise by 6.6% to $11.65 billion, indicating solid segment growth.
Risk Factors
  • Analysts project quarterly earnings per share of $7.46, which represents a year-over-year decline of 4.7%.
  • Pharmacy claim volume is expected to decrease slightly to 553.94 million from the year-ago figure of 558.00 million.
  • Covered lives in the International Health segment are forecasted to drop to 1.62 million compared to 1.71 million last year.
Full Analysis
Wall Street analysts project Cigna (CI) to report quarterly earnings of $7.46 per share, representing a year-over-year decline of 4.7%. Revenue is expected to reach $73.53 billion, marking a 5.7% increase from the prior-year quarter. Over the last 30 days, there have been no revisions to the consensus EPS estimate, indicating stability in analyst expectations despite the projected earnings drop. Analysts forecast specific segment revenues, with Evernorth Health Services expected to generate $64.06 billion (+6.1% YoY) and Cigna Healthcare generating $11.65 billion (+6.6% YoY). Within the U.S. Commercial segment, stop-loss premiums are projected at $2.18 billion (+14.1% YoY), while employer-insured premiums are estimated at $4.99 billion (+6.1% YoY). The Medical Care Ratio is anticipated to remain steady at 85.1%, slightly up from the year-ago value of 84.8%. Customer metrics show growth in total medical customers, which analysts estimate will reach 18.37 million compared to 18.06 million last year. Administrative services only customers are projected at 14.20 million for U.S. Healthcare, up from 13.79 million previously. However, pharmacy claim volume is expected to decrease slightly to 553.94 million from 558.00 million a year ago. International health covered lives are forecasted at 1.62 million, down from 1.71 million in the same quarter last year. Cigna shares have outperformed the broader market recently, rising 10.2% over the past month compared to the S&P 500's decline of 0.9%. Despite this recent strength, Zacks Investment Research maintains a Rank #3 (Hold) rating for CI, suggesting the stock is expected to mirror overall market performance in the near future rather than showing significant directional momentum based on current analyst consensus.